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Abstract
Background—Blacks have a higher incidence of colorectal cancer (CRC) and a younger age at 
diagnosis compared to Whites. Few studies have investigated racial differences in risk of 
metachronous adenomas and serrated polyps whether this risk differs by polyp characteristics or 
age of patient.
Methods—We analyzed data pooled from three placebo-controlled adenoma chemoprevention 
trials to explore racial differences in the risk of large bowel polyps in patients ≤50 and > 50 years 
of age. Using generalized linear regression, we estimated risk ratios (RR) and 95% confidence 
intervals (CI) as measures of the association between race and risk of one or more adenomas or 
serrated polyps after randomization.
Results—Among the 2605 subjects who completed at least one follow-up exam, blacks ≤50 
years of age had a higher risk of any conventional adenoma (RR 1.70, 95% CI 0.99–2.92) and 
advanced neoplasms (RR 4.05, 95% CI 1.43–11.46) and a non-significantly lower risk of serrated 
polyps (RR 0.75 (95% CI 0.34–1.62) compared to whites. Among patients > 50 years there was no 
racial difference in risk of adenomas (RR 1.08, 95% CI 0.92–1.27) or advanced neoplasms (RR 
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1.05, 95% CI 0.71–1.56)). However, blacks had a significantly lower risk of serrated polyps (RR 
0.65, 95% CI 0.49–0.87) than whites.
Conclusions—Our results demonstrate a higher risk of metachronous adenomas in blacks 
compared to whites at younger ages.
Impact—Our results suggest that the racial disparity in CRC incidence may be due to an excess 
of neoplasia in younger blacks.
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Introduction
Colorectal cancer (CRC) is the second most common malignancy in the US among both 
men and women (1). The CRC incidence rate is 20% higher in blacks compared to whites, a 
disparity that has increased over the last twenty years (1–3). Invasive CRC most often 
develops from conventional adenomas or serrated polyps yet whether racial factors impact 
the incidence of CRC precursor lesions is not clear.
Several investigations have compared the prevalence of colorectal polyps by race at 
screening colonoscopy (4–8) and, most studies, but not all (9), have reported a higher risk 
among blacks compared to whites, especially for advanced or proximal lesions (5, 8, 10). 
Only a few studies have compared the risk of metachronous polyps by race and none has 
reported a significant difference in adenomas(11–13) but one observed a lower risk of 
serrated polyps in blacks compared to whites (14). The lack of a significant association in 
metachronous adenomas by race may be due to low statistical power, as there were few 
blacks undergoing follow-up exams in two (12, 13) of the three studies. Alternatively, 
because CRC is diagnosed at earlier ages and tends to be more aggressive in younger blacks 
compared to younger whites (15, 16), racial differences in recurrence at younger ages may 
be present in a subset of patients but the effect could be masked if all ages are combined in 
analysis. To disentangle the impact of race and age on risk of metachronous large bowel 
polyps, we pooled data from three large placebo-controlled adenoma chemoprevention 
trials. Specifically, we hypothesized that the association between black race and risk of any 
or advanced neoplasms would be stronger among younger than older patients undergoing 
follow-up colonoscopy.
Materials and Methods
This analysis was based on pooled data from three placebo-controlled, randomized 
colorectal adenoma chemoprevention trials: the Antioxidant Polyp Prevention Study (17); 
the Calcium Polyp Prevention Study (18); and the Aspirin Folate Polyp Prevention Study, 
(19) the details of which are reported elsewhere. Written informed consent was obtained 
from each participant and the Institutional Review Board of every participating institution 
approved the studies.
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All eligible subjects had one or more histologically confirmed colorectal adenomas and 
underwent a complete colonoscopy at baseline with the endoscopist attesting that all polyps 
were removed. For the Antioxidant and Calcium studies (17, 18), adenomas were required to 
be removed within 3 months before recruitment. For the Aspirin Folate study, eligible 
patients had at least one of the following: one or more colorectal adenomas removed within 
3 months before recruitment, one or more adenomas removed within 16 months before 
recruitment and a lifetime history of two or more confirmed adenomas, or a one or more 
adenoma at least 1 cm in diameter removed within 16 months before recruitment (19). 
Subjects were then randomized to the study agent or placebo with scheduled colonoscopic 
surveillance at one and four years after the qualifying examination in the Antioxidant and 
Calcium studies, and at three years in the Aspirin/Folate trial. Treatment ended at the year 
four examination in the Antioxidant and Calcium studies (risk defined as randomization to 
year 4) and at the year three examination (risk period defined as randomization to year 3) for 
aspirin in the Aspirin Folate Study (although folate treatment continued in most subjects) 
(20).
For the qualifying exam, clinical staff at each center abstracted data from the endoscopy and 
pathology reports on the total number of lifetime adenomas per subject for each of the three 
studies (i.e. Antioxidant, Calcium, and Aspirin Folate Polyp Prevention Studies). 
Information on adenoma size and histology were only available for Calcium Polyp 
Prevention Study (18), and the Aspirin Folate Polyp Prevention Study (19). During follow-
up exam(s), the location and estimated size of each colorectal lesion found was recorded and 
the polyps were removed and sent for central histological review by a single study 
pathologist.
For the main analysis, polyps were classified as serrated polyps (including: hyperplastic 
polyps, traditional serrated adenoma, sessile serrated adenoma) or conventional adenomas 
(tubular, tubulo-villous, and villous). Our primary endpoints were any conventional 
adenoma or serrated polyp that occurred after randomization in younger and older persons, 
including: polyps removed at the year one and four exams in the Antioxidant and Calcium 
studies (17, 19) and at year three exam in the Aspirin/Folate trial (19, 20). Serrated polyps 
were classified as a single category because the criteria for these lesions had changed over 
the course of the three polyp prevention studies (14). Advanced histology neoplasms were 
defined as conventional adenomas with at least a 25% villous component. Advanced 
neoplasms were defined as invasive cancer or conventional adenomas with at least a 25% 
villous component, high-grade dysplasia, or ≥1 cm in diameter. Colonic location was 
designated as either proximal (inclusive of the cecum, ascending colon, hepatic flexure, and 
transverse colon) or distal (inclusive of the splenic flexure, descending colon, sigmoid colon, 
and rectum).
At enrollment, participants completed a questionnaire assessing basic demographic 
characteristics, lifestyle factors, medical history (including height and weight), and usual 
diet (using a validated food frequency questionnaire). Subjects were also asked about family 
history of polyps and/or colorectal cancer. We analyzed demographic factors, including age, 
sex, and self-reported race. Smoking status was categorized as “never,” “former,” and 
“current” users. Alcohol use was categorized drinker (> 0 drinks per day) or non-drinker. 
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Body mass index (BMI) was calculated from baseline information on height and weight and 
divided into three categories using the standard established by the World Health 
Organization: normal (<25 kg/m2), overweight (25 to 29.9 kg/m2), and obese (BMI ≥30 
kg/m2). In the first two polyp prevention trials, height and weight were assessed by study 
personnel (physician’s initial assessment) and by self-report in the third study.
Statistical analysis
To assess the association between polyp type and race, we estimated risk ratios (and 95% 
confidence intervals) for one or more large bowel polyps after randomization, calculated 
with generalized linear regression analyses using a logarithmic linkage and a Poisson 
distribution. For the main analysis we examined the association between race and risk of any 
conventional or advanced neoplasm and any serrated polyp in patients ≤50 and > 50 years of 
age. Additionally, we examined race and risk of adenoma and serrated polyps in the 
proximal and distal colorectum. The decision to stratify our results by age was guided by an 
a priori hypothesis that the racial disparity in metachronous polyps would be more 
pronounced among younger patients compared to older, based on the fact that younger 
blacks compared to younger whites may have more aggressive CRC features and poorer 
outcomes (15, 21–23). We used Wald tests to assess main effects and statistical interactions. 
All effect estimates were adjusted for age, sex, treatment assignment, and follow-up time.
Results
Of the 2683 subjects who self-identified race as black or white, 2605 (97.1%) completed at 
least one follow-up exam after randomization. The mean age of the study participants was 
59.8 years (SD (9.3)), 71.3% were men, and 7.5% of patients were black. The mean length 
of follow-up from time of randomization to final study exam was 38.6 (SD (9.8)) months.
Overall, we did not observe a significant association between black race and risk of any 
conventional adenoma, or advanced neoplasm. The RR for blacks compared to whites for 
risk of any metachronous conventional adenoma was 1.11 (0.95–1.31) and any advanced 
lesion was 1.18 (0.82–1.71). We observed a statistically significant increased risk of any 
right-sided conventional adenoma 1.25 (1.02–1.53) but no significant increased risk 
observed for the left colorectum, 1.13 (0.89–1.43). Overall results for serrated polyps were 
published previously (14). The interaction between race and age ≤50 years was p=0.17 for 
any conventional adenoma, p=0.03 for advanced histology adenoma, p=0.04 for any 
advanced neoplasm and p=0.67 for serrated polyps. Results stratified by patients ≤50 years 
of age are shown below.
Patients ≤ 50 years old
At study entry, blacks had a lower prevalence of family history of CRC polyp or cancer and 
a higher prevalence of diabetes and a greater mean number of large adenomas (Table 1). 
Some other baseline characteristics appeared to differ by race (black compared to white), but 
were not statistically significant, including: obesity (+17%), current smoker (+14%) 
hypertension (+13%) (Table 1).
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During the follow-up period, younger blacks compared to younger whites had a higher risk 
of one or more conventional adenomas, advanced histology adenomas, and any advanced 
neoplasm (Table 2). Adjustment for number of large baseline adenomas did not appreciably 
affect the RR for race: conventional adenoma RR was 1.85 (95% CI 0.99–3.48), advanced 
histology adenoma was RR was 5.31 (95% CI 1.57–18.0), and any advanced adenoma was 
3.77 (95% CI 1.16–12.3)). The percentage of serrated polyps was 24% in younger blacks 
and 30% in younger whites (Table 2). Associations for black race and adenoma outcomes 
were not appreciably different after adjusting for several other covariates (one at a time) 
such as smoking status, alcohol use, family history of CRC, body mass index, hypertension, 
high cholesterol, diabetes, or caloric intake (data not shown). RR for race and risk of 
adenoma or serrated polyp outcomes were similar across for each of the three polyp 
prevention study cohorts despite changes in the definition of serrated lesions during this time 
frame (data not shown).
Patients > 50 years of age
We observed that, at baseline, older blacks compared to older whites were significantly less 
likely to be male (−14%), have a family history of CRC (− 9%) and to report consuming 
alcohol (−16%). On the other hand, blacks were significantly more likely to be current 
smokers (+11%), hypertensive (+20%), and obese (+9%). We did not observe a difference in 
baseline adenomas by race (Table 1).
During the follow-up period, older blacks had a similar risk of conventional adenoma, 
advanced adenoma and a significantly lower risk of serrated polyps compared to whites 
(Table 2). Black race was associated with non-significantly higher risk of proximal 
conventional adenomas but no statistical difference in the distal colorectum (Table 2).
Discussion
Overall, in this pooled analysis, our primary finding, supporting our hypothesis based on 
CRC data, was that younger blacks had significantly more large adenomas at baseline and a 
higher risk of any conventional or advanced metachronous adenomas. Younger blacks 
tended to have a lower prevalence of family history of CRC and higher prevalence of 
diabetes but neither of these factors, nor several other variables we interrogated as potential 
confounders (e.g. smoking status, alcohol use, diabetes, high cholesterol, hypertension, 
number or size of baseline adenomas) appreciably changed our results. Blacks older than 50 
years compared to whites had a similar risk of any conventional or advanced adenomas and 
a lower risk of serrated polyps. Although we observed several differences in baseline 
characteristics between older patients by race, these differences did not affect the association 
of race and the risk of metachronous lesions.
To our knowledge, our study is the first to specifically examine the relationship between 
race and risk of metachronous neoplasms among a set of patients below and above fifty 
years of age. No previous studies have reported a difference by race and metachronous 
adenomas. One reason for the lack of a statistical association in previous studies may be the 
small numbers of blacks undergoing follow-up colonoscopy (11–13). In the Penn et al. 
study, for example, there were only 7 black patients who had surveillance colonoscopy and 
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the RR was increased, but not significantly (RR 1.89 (95% CI 0.68–5.24); in the Laiyemo et 
al. investigation (13) recurrence risk was similar by race for any adenoma but non-
significantly increased for advanced (RR 1.18 (95% CI 0.68–2.05) and advanced proximal 
lesions (RR 1.31 (95% CI 0.59–2.91). Another reason for finding no significant difference 
by race and recurrence could be due to the age structure of the population in which these 
associations were examined. It is well established that sporadic CRC in younger persons is 
known to be more aggressive histopathologically (24–28) and is found at later stages (24, 
26–30). Blacks are consistently diagnosed at a younger age and later stage of disease 
suggesting that differences in incidence and outcome could be related to a more aggressive 
phenotype among a subset of patients. In support of this idea, recent reports among those 
with invasive CRC have found that younger blacks, compared to younger whites have more 
aggressive histologic features at diagnosis and poorer CRC outcomes (15, 16, 22, 23).
Additionally, there is significant data to suggest a higher prevalence of aggressive neoplasia 
in blacks undergoing screening exams. In one of the earliest reports to examine polyp 
prevalence by race, Lieberman and colleagues (10) found that blacks had a higher risk of 
larger polyps (> 9mm) compared to whites, especially African-American women. Lebwohl 
and colleagues (5) found an increased risk among blacks compared to whites of proximal 
and advanced neoplasm but also reported an association with any adenoma (OR 1.76 (95% 
CI 1.52–2.04)) findings which were recently corroborated by Sanchez et al. (RR 3.0 (95% 
CI 1.1–8.3))(7). Others(8, 9), however, have observed a similar risk of prevalent and 
advanced adenomas by race, but a higher risk of proximal adenomas in blacks compared to 
whites – proximal location is associated with poorer survival among patients with invasive 
cancer (31–33). Because these studies include prevalent adenomas detected at screening 
exams (typically after the age of 50), the age at which these adenomas form is not known, 
yet higher rates of advanced polyps at first screening exam suggests that a subset of blacks 
either have more aggressive adenoma growth rates and/or develop adenomas at an earlier 
age.
The present investigation demonstrates a higher recurrence of any conventional and 
advanced neoplasms among younger but not older blacks compared to whites. The reason 
for this is unclear, but suggests that there may be differences in the rate of carcinogenesis in 
a subset of younger patients or proclivity to develop polyps within a more aggressive 
pathway. Increasingly, CRC is a recognized as heterogeneous disease, which can evolve 
through distinct pathways at varying rates (34–40). CRC can be broadly separated into three 
pathways evolving through (1) the chromosomal instability pathway (CIN) which tend to 
arise from conventional adenomas and (2 &3) CpG island methylated pathway(s) (CIMP I & 
CIMP II) (34–40) which appear to arise from serrated lesions (sessile serrated polyps and 
traditional serrated adenomas). Our results suggest that younger black patients may be more 
likely to develop metachronous adenomas through the CIN pathway. Older blacks had a 
reduced risk of serrated polyps compared to whites but our data did not allow us to make a 
conclusive judgment regarding risk of serrated polyps in younger blacks because of the 
small sample size. Previously, we observed a reduced risk in serrated polyps among all ages 
combined (14) which was similar to what others (41–43) have also reported. These results 
speak against a methylated milieu, but future studies will be needed to determine if this is 
true by measuring whether the pathologic and molecular features differ by race. Future 
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studies should also aim to include patients with conventional adenomas and/or serrated 
polyps at the qualifying exam in order to adequately assess the risk of different types of 
metachronous lesions by race.
Our study had several limitations. First, all of our patients had to have at least one adenoma 
at to be eligible for the study, these patients may differ from average risk patients. Second, 
patients participating in a chemoprevention trial are likely a select group and also likely 
differ from the general population. We also had a very small number of younger black 
patients, especially among those less than 50 years of age. All of these factors may limit the 
generalizability of our findings. We also lacked information on potential important 
confounders, such as, physical activity level. Further, we did not have detailed pathologic 
information on the histology of the serrated lesions and all of our patients had a documented 
conventional adenoma at baseline -- whether the risk of metachronous serrated polyps would 
have differed in patients with a serrated adenoma at baseline is not known and requires 
further study. Additionally we used self-identified race which may increase the possibility of 
misclassification bias. Strengths of the study include a large population of white patients, 
central pathological review, and standard follow-up by protocol. To date, this is the largest 
study, despite the limitations cited above, that has looked at the risk of metachronous 
adenomas by race in younger and older age groups.
The American College of Gastroenterology recommends that average risk blacks incept 
CRC screening at age 45 years rather than age 50 years because of the earlier age of onset of 
CRC, higher stage at diagnosis and increased stage adjusted mortality compared to whites 
(44). Our data showing a greater number of large baseline adenomas and advanced 
adenomas in blacks ages ≤50 years compared to whites of the same age would support that 
recommendation. Overall, the results of our study provide some evidence that the racial 
disparity in CRC incidence may be due, in part, to an excess of neoplasia in younger blacks. 
Much larger studies will be needed to confirm these findings.
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